# Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy

> **NCT00470977** · PHASE1,PHASE2 · COMPLETED · sponsor: **Manhattan Eye, Ear & Throat Hospital** · enrollment: 18 (actual)

## Conditions studied

- Coats' Disease
- Idiopathic Retinal Telangiectasia
- Retinal Angiomatous Proliferation
- Polypoidal Choroidal Vasculopathy
- Pseudoxanthoma Elasticum
- Pathological Myopia
- Multi-focal Choroiditis
- Rubeosis Iridis
- Von Hippel Lindau Disease
- BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)

## Interventions

- **DRUG:** ranibizumab injection (0.5 mg)

## Key facts

- **NCT ID:** NCT00470977
- **Lead sponsor:** Manhattan Eye, Ear & Throat Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2012-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00470977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00470977, "Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00470977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*